Brain Tumor Exosomes and Microvesicles: Pleiotropic Effects from Tiny Cellular Surrogates by Michael W Graner
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Brain Tumor Exosomes and Microvesicles:   
Pleiotropic Effects from Tiny Cellular 
Surrogates 
Michael W Graner 
University of Colorado Denver 
Anschutz Medical Campus 




Extracellular signaling is a necessity for tissue and organ system development, maintenance, 
adaptation and survival. From the biologic unit of the cell to the complete organizational 
structure that is the organism, cell-cell, cell-tissue, tissue-organ, and organ-system 
communication are essential to keep the organism functioning, homeostatic, and 
proliferative. Cell-derived extracellular vesicles such as exosomes and microvesicles are 
vital players in these forms of proximal and distal messaging, acting as discrete packets of 
information capable of altering recipient cell phenotypes, activities, and responses. These 
vesicles are part of the normal biologic repertoire of the organism, but are particularly 
exploited by neoplasmic growths and cancers to change both the local and systemic 
environments to aid in tumor proliferation, invasion, and metastases, and in the defense of 
the tumor. This chapter will focus on exosomes and microvesicles from brain tumors, but 
similar stories may be told about such vesicles from almost any tumor type. Following this 
general introduction on exosomes and microvesicles we will discuss the experimentally 
determined and putative roles of exosomes in brain tumor biology, particularly in stress 
responses, metabolism, migration, immunology, and protection against chemotherapeutics. 
2. Exosome/Microvesicle biosynthesis simplified 
The interactions between cell surface components, extracellular matrix molecules, proteases 
and protease inhibitors, and “soluble” factors is complex (Weber, Bjerke, and Desimone ; 
Rozario and DeSimone ; Chirco et al. 2006; Gonzalo et al. ; Kessenbrock, Plaks, and Werb ; 
Stetler-Stevenson 2008; Hyytiainen, Penttinen, and Keski-Oja 2004; Tran, Griffith, and Wells 
2004; Goldman 2004). However, the distinction between truly soluble factors and technically 
particulate forms of those factors becomes blurred in terms of exosomes and microvesicles 
(Peinado, Lavotshkin, and Lyden ; Camussi et al.). Exosomes and microvesicles are cell-
derived, bilayer membrane-enclosed nanovesicles ranging from virus-sized entities (eg, 
exosomes, 30-100 nm diameter) to small bacteria-sized (eg, microvesicles, ~150 nm- 3000 nm 
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diameter ) (Johnstone 2006)—ie, “fat balls”. These vesicles exist essentially anywhere there is 
a cell-liquid interface such as in blood, urine, semen, breast milk, bronchoalveolar lavage 
fluid, synovial capsule fluid, saliva, ascites, amniotic fluid, cerebrospinal fluid, and in vitro 
spent culture media (Simpson et al. 2009). The obtuse vesicular nomenclature and lack of  
molecular definitions for these microparticles generates confusion (Mathivanan, Ji, and 
Simpson); in this chapter, for these cell-derived vesicles we will refer to exosomes as 
extracellularly-released components of the endocytic pathway, while microvesicles will refer 
to “shed” vesicles released directly from cell-surface membrane budding (Figure 1). Please 
note that in this work “exosome” does not refer to the intracellular multi-subunit RNA 
processing complex (Mitchell et al. 1997). 
Due to the directional nature of the biogenesis of the two forms of vesicle formation, 
exosomes and microvesicles largely retain the original topography of the cell itself, making 
these vesicles akin to tiny cellular surrogates (Figure 2). The contents include selected 
membrane lipids such as gangliosides GM1 and GM3, sphingomyelin, lyso-bis-phosphatidic 
acid/bis-monoacylglycerol phosphate (LBPA/BMP), and cholesterol. Protein contents are 
also strikingly conserved across exosomes and microvesicles from various cell types, 
including protein components of lipid raft membrane structures, tetraspanins, numerous 
metabolic enzymes, heat shock proteins, structural proteins, and nucleic acid binding 
proteins (Simpson, Jensen, and Lim 2008). Appropriately, messenger and microRNAs are 
also present in exosomes (Taylor and Gercel-Taylor 2008; Valadi et al. 2007) including those 





Fig. 1. Highly diagrammatic representation of the release of extracellular vesicles from a cell. 
Two basic mechanisms are depicted: 1) shedding or “blebbing” of vesicles directly from cell 
membrane surface, yielding microvesicles (sometimes called microparticles or “ectosomes”); 
2) following the endocytic pathway, endosomal compartments develop invaginations that 
bud off into the endosomal lumen as small vesicles. The endosome is now called a 
multivesicular body (MVB). At this stage, the MVB may fuse with the lysosome for 
degradation and recycling of its contents. However, if the MVB fuses with the cell 
membrane, the vesicles within it are exocytically released as exosomes. 
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they retain sufficient cell-specific material to frequently allow identification of the cell type 
source of origin (Denzer et al. 2000; Bobryshev et al. 2001; Blanchard et al. 2002; Graner et al. 
2009; Skog et al. 2008). Given that these durable vesicles, when released by tumors, circulate 
in blood and are found at particularly high levels in patients with cancer (Taylor and Gercel-
Taylor 2008), exosomes and microvesicles are considered potential sources of biomarkers 
obtainable with minimally invasive procedures (Duijvesz et al. ; Krutovskikh and Herceg ; 
Simpson et al. 2009), including from urine (Dimov, Jankovic Velickovic, and Stefanovic 2009; 
Pisitkun, Johnstone, and Knepper 2006). 
 
 
Fig. 2. The topography of exosomes mimics that of the cell of origin. Depicted is a highly 
diagrammatic cartoon of exosome formation showing the endocytosis of transmembrane 
proteins (purple lines) in the context of the outer lipid layer of the plasma membrane 
(shown in red) and the inner lipid layer facing the cytosol (shown in blue). During 
endosome formation, the cytoplasmic portion of the membrane protein remains in the 
cytosol; as the endosomes fuse to become more mature structures, invaginations occur, 
resulting in the pinching off of small vesicles into the luminal space of the endosome. These 
smaller vesicles may be referred to as intravesicular bodies (“IVBs”) while the whole 
structure is denoted as a multi-vesicular body (“MVB”). The former intracellular domain of 
the transmembrane protein is now sequestered away from the cytosol; cytoplasmic contents 
also enter the IVB during formation (green dots). The typical fate of the MVB is fusion with 
a lysosome for content degradation and recycling. However, if the MVB instead fuses with 
the plasma membrane, the IVBs will be release extracellularly, and are now called 
“exosomes”. Note that the membrane topography (red/blue positioning) and 
transmembrane protein orientation are the same as that of the original cell. 
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The mechanisms driving vesicle formation (at the level of invagination into the endosomal 
lumen and in the direct “blebbing” from the cell surface) have many of the same driving 
components, particularly the ESCRT (Endosomal Sorting Complex Required for Transport) 
machinery including ALIX/AIP1 (de Gassart et al. 2004) and PI3 kinase and related 
molecules (Stoorvogel et al. 2002). Lipid composition is also a key factor, with structure-
altering, membrane-bending lipids playing key roles in the curvature-induced vesicular 
invaginations (Trajkovic et al. 2008; Subra et al. 2007; Laulagnier et al. 2005) . The acidic pH 
of the endosomal lumen also enhances lipid bending away from the limiting membrane 
(Subra et al. 2007) and the low pH of the tumor microenvironment likely has similar effects 
on microvesicle budding and extracellular activity of the vesicles (Giusti et al. 2008), 
including exosomes (Parolini et al. 2009). As lipid moieties such as the 
phosphoinositides/phosphoinositol phosphates (PIPs) and proteins such as the Rab proteins 
are important in intracellular vesicular identification and trafficking (Perret et al. 2005), it is 
not surprising that these entities also play significant roles in extracellular vesicle formation 
(Ostrowski et al. ; Hsu et al.)  Various membrane-fusion proteins of the SNARE families are 
also likely involved (Thery, Zitvogel, and Amigorena 2002). Thus, the intra- and 
extracellular environments, various lipid players, and numerous proteins involved in 
intracellular vesicle identity and function all play roles in the formation , intracellular 
targeting, and possibly extracellular targeting,  of exosomes and microvesicles.  
2.1 Basics of exosome/microvesicle cargo loading: filling up the fat balls 
The sorting process/cargo loading of exosomes and microvesicles is still largely a mystery; 
whether certain proteins are destined or chosen to become vesicle content or are “trapped” 
into them is not clear. However, some fundamental principles seem to hold. One of the most 
common protein post-translational modifications that results in a vesicular destination is 
ubiquitination, frequently from E3 ubiquitin ligase activities; this may be regulated to some 
extent by deubiquitination complexes such as signalosomes (Liu et al. 2009). Curiously, cells 
that are the recipients of exosomes may also activate ubiquitin ligases as part of the 
downstream effects of extracellular vesicle interactions (Qu et al. 2009). There are also likely 
ubiquitination-independent mechanisms for vesicular assimilation of proteins as well 
(Gauvreau et al. 2009); these may include potentially ESCRT- or Rab-driven incorporation of 
proteins into a “frustrated” recycling pathway where the proteins are neither returned to the 
cell surface nor directed toward the lysosome (de Gassart et al. 2004). Curiously, lipid 
sorting into such compartments is a function of the length and/or saturation of their alkyl 
tails (Mukherjee, Soe, and Maxfield 1999). LBPA, an unconventional negatively-charged 
phospholipid, is also sequestered to late endosomes/MVBs with a potential structural role 
(Matsuo et al. 2004). Since LBPA is mostly enriched in internal membranes, whether it plays 
a role in plasma membrane dynamics is unclear. Membrane partitioning such as lipid raft 
formation is also a key player in exosome and microvesicle biogenesis and sorting (de 
Gassart et al. 2003; Calzolari et al. 2006; Staubach, Razawi, and Hanisch 2009; Del Conde et 
al. 2005). Proteins contained within those lipid rafts are thus sorted to exosomes and 
microvesicles and include GPI-linked proteins such as acetylcholinesterase (Graner et al. 
2009), the NKG2D ligands MICA and MICB (Hedlund et al. 2009), Gce1 and CD73 (Muller et 
al. 2009), and CD55 and CD59 (Rabesandratana et al. 1998), etc. As mentioned above, the 
gangliosides GM1 and GM3 are also present in lipid membrane microdomains (Janich and 
Corbeil 2007) and in exosomes (de Gassart et al. 2003; Parolini et al. 2009). 
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Membrane proteins that are not necessarily typical constituents of lipid raft domains may 
shuttle into exosomes or membrane patches of microvesicles by aggregation, such as the 
transferrin receptor (de Gassart et al. 2004) or by “higher-order oligomerization” induced by 
antibody cross-linking at the cell surface, or by artificially acylation tagging of cytosolic 
proteins resulting in oligomerization and trafficking to released microvesicles (Fang et al. 
2007). Further studies have shown that a variety of membrane anchors can target proteins to 
exosomes and microvesicles, but not all with the same efficiency (Shen et al.). A number of 
other membrane proteins are typically found in exosomes and microvesicles and are 
hallmarks of them. These include members of the tetraspanin network such as CD9, CD9P-1 
TSPAN8, CD63, CD81, and CO-029 (Abache et al. 2007; Gesierich et al. 2006; Pols and 




Fig. 3. Functional analysis of the proteomic content of exosomes/microvesicles derived from 
D283MED medulloblastoma cells. Over 130 proteins were identified by extraction of 
proteins from vesicles, separation of the proteins on SDS-PAGE, excision of the bands from 
BioSafe Coomassie Blue-stained gels, and tryptic digest of the excised bands. Peptides were 
separated and analyzed by LC-MS/MS, and peptides were mapped or identified by de novo 
sequencing using PROWL and Sequest algorithms. Proteins were categorized with 
Ingenuity Pathway Analysis software and by literature searches focusing on known 
functions; please note that many of the proteins identified were multifunctional, and this 
categorization represents the preponderance of evidence for function based on present 
literature. 
Many cytosolic proteins (or at least many that are not widely recognized to have membrane 
associations) are exosome components; these include members of the heat shock protein 
(HSP) family, HSP/HSC70 and HSP90 in particular, and numerous metabolic enzymes. We 
have identified these proteins previously in proteomic studies of murine brain tumor 
exosomes and have cataloged and categorized them (Graner et al. 2009). We have performed 
further proteomic studies on human brain tumor exosomes (from the medulloblastoma cell 
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line D283MED) which confirm and extend the results of the murine studies. In particular, 
metabolic enzymes represent the largest class of exosome proteins (Figure 3). While their 
prevalence may reflect their cellular abundance, there is a clear enrichment of these proteins 
in exosomes/microvesicles. 
2.2 Functions and activities of tumor exosomes/microvesicles: fun with fat balls 
Originally regarded as a means of cellular content disposal, particularly if cells lack 
lysosome activity (Johnstone et al. 1987; Johnstone, Bianchini, and Teng 1989) (ie, “garbage 
bags”), exosomes and microvesicles have an extensive and increasing list of activities, roles, 
and functions locally and systemically when released by tumors into the extracellular 
environment. Here we will briefly overview some of those better-characterized activities, 
most of which are regarded as beneficial to the tumor in terms of growth, invasion, or 
protection. 
2.2.1 Immunologic effects: floating fat balls as stimulators or suppressants? 
Exosome/microvesicle studies in tumors were originally driven by the idea that as tiny, 
non-replicating cellular surrogates, these vesicles could be used as cell-free anti-cancer 
vaccines. The premise was that exosomes and microvesicles contained tumor-specific 
antigens (Andre et al. 2002; Cho et al. 2005) as a source of adaptive immune cell targeting. In 
addition, exosomes/microvesicles contain heat shock proteins, known “danger signals” that 
both carry peptide antigens themselves as well as provide a potent, adjuvant-like stimulus 
to the innate and adaptive immune systems, particularly at the level of antigen presenting 
cells (Graner and Bigner 2005, 2006).  
2.2.1.1 Dendritic Cell Exosomes (“DEX”) 
The initial works using exosome-based vaccines utilized exosomes derived from antigen-
pulsed dendritic cells (DCs). DCs are perhaps the most effective “professional” antigen 
presenting cells known (Banchereau et al. 2000), and like all immune cells, one important 
means of extracellular communication for them is via the release of exosomes and 
microvesicles (Chaput et al. 2006). DCs process and present antigens to CD4+ and CD8+ T 
cells (“helper” cells and “cytotoxic or killer”/cytotoxic T lymphocyte/CTL cells, 
respectively), and if appropriately activated, will prime and stimulate the T cells for 
enhanced immune activities. From a clinical perspective, antigen-loaded and ex vivo 
activated DCs have been used in immunotherapy protocols as anti-cancer vaccines for a 
wide variety of tumor types and using an extraordinary range of antigen sources that are 
“pulsed” (applied to) the DCs (Palucka et al.). In general, in vitro (or ex vivo) DC production 
protocols are not standardized, require a great deal of hands-on time and effort, and the 
resulting cell preparations can be difficult to freeze and recover from thawing for  repeated 
patient treatment (de Vries et al. 2005; Kalinski et al. 2009; Simon, Fonteneau, and Gregoire 
2009). Exosomes and microvesicles from DCs (sometimes called “dexosomes” or “DEX”) can 
be harvested from the culture supernatants, stored frozen, and thawed without loss of 
stimulating activity. They can be injected into hosts as cell-free DC-type vaccines capable of 
stimulating anti-tumor responses. These DEX were the first exosome-based vaccines 
(Zitvogel et al. 1998); DEX are capable of transferring antigen-loaded major 
histocompatibility class I molecules (MHC I) to recipient DCs for priming of naïve T cells in 
the host (Andre et al. 2004). These DC-derived vesicles were produced in a large-scale GMP 
setting (Lamparski et al. 2002) and were used to treat patients with metastatic melanoma in 
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a clinical trial; the vaccines were safe, feasible, and produced  one partial response with 
signs of specific immunity (Escudier et al. 2005). Another trial for patients with non-small 
cell lung cancer achieved similar results with some patients maintaining stable disease 
(Morse et al. 2005). As is the case for most immunotherapies, more work is needed on 
disabling the tumor-induced immune suppression and perhaps choosing patients with less 
tumor burden and lower stage, less advanced cancers to improve responses and outcomes. 
Nonetheless, the safety and feasibility of DEX as clinically-usable entities is evident; further 
advances in safe and tolerable immune stimulation, and the means to “suppression the 
suppression” of immunity driven by tumors are desperately needed. 
2.2.1.2 Tumor-derived Exosomes (“TEX”) 
Tumor-derived exosomes (sometimes call “TEX”) also have a history as vaccine material; as 
mentioned above, their antigen content and HSP-based adjuvant effects theoretically make 
them ideal cancer vaccines. This has proven true in a number of animal models of cancer 
(Altieri, Khan, and Tomasi 2004; Dai et al. 2005; Chen, Wang et al. 2006; Bu et al. 2006; Cho 
et al. 2009; Graner et al. 2009). One clinical trial performed in China using autologous tumor-
derived (from ascites fluid of colorectal cancer patients) combined (or not) with the immune 
stimulant GM-CSF has been reported. One patient treated with both TEX and GM-CSF had 
stable disease, and another in that group had a partial response.  In immune assays, 
delayed-type hypersensitivity (DTH) reactions were seen in patients immunized above a 
threshold amount, and selected patients had positive CTL assays (tetramer staining, 
cytotoxicity, interferon-gamma (IFN) release). No serious adverse events were reported 
(Dai et al. 2008). This trial seemed to bear out results from animal models. However, much 
of our current thought regarding TEX immunology is dominated by the pervading opinion 
that tumor-derived exosomes are purveyors of immune suppression thru increased 
regulatory T cell (Treg) activity, myeloid-derived suppressor cell activity, and suppression 
of activated T cells, natural killer (NK) cells, and inhibiting DC maturation (Taylor and 
Gercel-Taylor 2005; Liu et al. 2006; Valenti et al. 2007; Ichim et al. 2008; Xiang et al. 2009; 
Szajnik et al.). There is also evidence that TEX can prevent the binding of anti-tumor 
antibodies to their tumor-expressed target by essentially titrating out the antibodies, thus 
preventing antibody-dependent cellular cytotoxicity (ADCC) (Battke et al.). While a few of 
these studies have been performed in in vivo settings, most of the data are from human cells 
in in vitro assays. Thus, the complex interplay of in vivo and systemic immunity and immune 
suppression may be poorly represented in these assays, and our results in this area will be 
discussed later. 
2.2.2 Coagulation and thrombosis: fat balls and clotting 
Microvesicles, especially those derived from platelets, have long been known as 
procoagulant players in clot formation, particularly when the vesicles carry tissue factor (TF) 
(Freyssinet and Toti). There is an increasing awareness that microvesicles may also have 
roles in some of the thrombotic events that can occur in cancer (Aharon and Brenner 2009; 
Castellana, Kunzelmann, and Freyssinet 2009) indicating an interplay between microvesicles 
from other “normal” cell types such as platelets reacting with cancer cells. However, tumor-
derived exosomes and microvesicles are also likely involved in this cellular cross-talk as 
well (Milsom et al. 2008), with the potential for coagulation to aid in delivery of growth 
factors or other stimuli to tumor cells. Tumor-derived microvesicles are believed to be partly 
responsible for Trousseau’s syndrome, a coagulopathy associated with the cancerous state 
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(Varki 2007); the involvement of tumor vesicles likely involves the presence of TF on their 
surfaces (Del Conde et al. 2007). These studies further indicate the systemic roles that tumor 
cell-derived vesicles may play in cancer growth, progression, and generation of other co-
morbidities in cancer patients. 
2.2.3 Signaling capacity:  influential fat balls 
Exosomes and microvesicles are carriers of protein and lipid molecules with direct and 
indirect signaling capacities and complexes (Record et al. ; Zumaquero et al.) including 
members of the EGFR family (Sanderson et al. 2008) including Her2/Neu/ErbB2 (EGFR2) 
(Ciravolo et al.) and the tumor-specific mutant EGRFvIII (Graner et al. 2009; Al-Nedawi et 
al. 2008). Importantly, both EGFR and EGFRvIII may actually passage from exosomes to 
recipient cells, leading to activation of those pathways with phenotypic changes induced in 
the recipient cells (Al-Nedawi et al. 2009). In addition, tumor exosomes and microvesicles 
also carry active EGFR ligands such as amphiregulin (Higginbotham et al.), thus indicating 
that the vesicles can carry not only the signal transducer, but the signal as well. 
Much of the signaling in cancer cells is devoted to proliferative drive. Exosomes and 
microvesicles are known to drive proliferation of tumor cells that are exposed to the vesicles 
(Koga et al. 2005; Skog et al. 2008); we have seen similar proliferation when pediatric and 
adult brain tumor cells are exposed to their endogenous exosomes (data not shown). 
Exosome-driven proliferation has been associated with the presence of the anti-apoptotic 
protein survivin in tumor exosomes (Khan et al.), and in a potential recruitment 
phenomenon, tumor microvesicles can enhance endothelial cell proliferation (Hong et al. 
2009) which presumably may promote tumor vascularization. The mechanisms behind these 
proliferative responses are not clear, although we have evidence that exosomes increase 
overall glycolytic metabolism of recipient cells (see below) which may be either a cause for 
cell growth or a means to abet it. To further complicate the issue, there is at least one report 
in the literature of tumor exosomes/microvesicles inducing apoptosis in the recipient tumor 
cells (Ristorcelli et al. 2008), so it is possible that exosome effects may be cell-type or cell 
context specific. 
2.2.4 RNA transport:  fat balls as diplomatic satchels 
As noted above (Figure 3) exosome/microvesicle proteomics revealed a relatively high 
percentage of RNA binding proteins typically present in exosomes. Since the biogenesis of 
exosomes and microvesicles intersects with some pathways of intercellular transmission of 
viruses, particularly at the levels of endosome (de Gassart et al. 2004; Mercer, Schelhaas, and 
Helenius) (also, see below), researchers began asking if exosomes and microvesicles 
themselves might have actual viral qualities, such as the ability to transport and transfer 
RNA molecules to recipient cells. This was first answered by Valadi et al (Valadi et al. 2007) 
when they demonstrated that exosomes did indeed possess both messenger and micro 
RNAs (mRNAs, miRNAs). Encapsulated in the vesicles, these RNAs were highly resistant to 
degradation by RNAses; furthermore, they demonstrated that mRNAs from one cell type 
could be passaged to another cell type, even of a different species (ie, mouse to human) 
resulting in translation of at least some of those messages (ie, humans cells now making 
mouse proteins). The numbers of mRNAs in exosomes/microvesicles and the genes 
represented by them are impressive (Mathivanan, Ji, and Simpson). One study involving 
brain tumor exosomes/microvesicles found that essentially the entire mRNA “expressome” 
is present in the population of collected vesicles, but there was significant enrichment for 
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certain mRNAs in exosomes/microvesicles that did not mirror the mRNA expression 
distributions from cells of origin (Skog et al. 2008). This type of horizontal transmission of 
epigenetic materials exists with normal cell types (Ogawa et al.) and even with viable tissues 
in culture (Aliotta et al.) as well as with tumor cells communicating with normal cells (Hong 
et al. 2009). 
microRNAs are recently-discovered small (22-25 nucleotide) non-coding RNAs that have 
potent regulatory potential (Carrington and Ambros 2003). miRNAs act as silencing RNAs, 
binding in an antisense fashion to regions of the 3’ untranslated regions (3’ UTRs) of 
mRNAs, resulting in either destabilization and degradation of the message, or prevention of 
translation; the net effect is translational repression of the message (Nelson et al. 2003). 
Following the discovery of miRNAs in exosomes (Valadi et al. 2007) there has been an 
explosion in the study of miRNAs in exosomes/microvesicles (for example, (Taylor and 
Gercel-Taylor 2008; Hunter et al. 2008; Rosell, Wei, and Taron 2009; Luo et al. 2009; Kosaka 
et al. ; Wang et al.)). There has been a particular emphasis on using circulating miRNAs (ie, 
those present in patient blood/serum) as disease biomarkers, presumably in the form of 
circulating exosomes/microvesicles (Rabinowits et al. 2009; Michael et al. ; De Smaele, 
Ferretti, and Gulino ; Kosaka, Iguchi, and Ochiya ; Wittmann and Jack ; Corcoran et al.). 
Thus, messenger and micro RNAs, when delivered to cells in the context of exosomes and 
microvesicles, have the potential to almost act virally by passaging epigenetic materials that 
could alter the phenotypes of the recipient cells. This represents an extraordinary form of 
extracellular communication, with vesicles as either mechanisms for delivery of RNAs, or 
perhaps as reservoirs to rapidly dispose of the RNA messages or regulatory activities. As 
biomarkers, the major advantage of such “circulating” RNAs over proteins or other subjects 
of molecular diagnostics is the ability to amplify the nucleic acid signal using PCR-based 
techniques, providing both increased signal and high specificity for the same biomarker, 
and relatively cheaply compared to some of the mass spectrometry or NMR methods 
needed for protein and metabolite markers. 
2.2.5 Passage of pathogens / pathogenic entities: fat balls gone bad 
As alluded above, the association of virus internalization, component packaging, and release 
in association with vesicles of the MVB and endosomal complexes or membrane lipid raft 
regions (Calistri et al. 2009) has prompted study of relationships between viruses and 
exosomes/microvesicles. For Human Immunodeficiency Virus (HIV), it has been proposed 
that the virus may hijack the system and egress from the cells via the plasma membrane 
microvesicle pathway (Booth et al. 2006) and from the exosome pathway (Nguyen et al. 
2003), leading to the “Trojan exosome” hypothesis (Gould, Booth, and Hildreth 2003). 
However, this concept remains controversial (Coren, Shatzer, and Ott 2008). Epstein-Barr 
Virus (EBV) has been another well-studied virus in the exosome/microvesicle field, where it 
was first noticed that the EBV protein LMP1 appears in exosomes from EBV-infected cells 
(Flanagan, Middeldorp, and Sculley 2003; Keryer-Bibens et al. 2006). The presence of LMP1 
and the immunomodulatory protein galectin-9 in exosomes derived from infected cells are 
implicated in immune suppression of NK and T cells, particularly affecting the 
inflammatory Th1-type responses (Dukers et al. 2000; Klibi et al. 2009). Hepatitis B and C 
viruses (HBV, HCV) are embedded in the etiology of hepatocellular carcinomas; envelope 
proteins from these viruses appear in exosomes from infected cells, and HBV requires MVBs 
for production of enveloped virons while subviral particles are released differently 
(Masciopinto et al. 2004; Watanabe et al. 2007). Human Herpes Virus 6 (HHV-6), an 
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immunosuppressive, neurotropic virus, also has associations with hematologic and CNS 
malignancies (Ogata 2009; Saddawi-Konefka and Crawford). As with other viruses, mature 
virons in infected cells were found in MVB-like compartments and released in exosome-like 
vesicles. It is not known if these viron-containing exosomes are infectious, but the 
implications of infection and immune suppression aiding tumor take and progression are 
obvious. Finally, Cytomegalovirus (CMV) has become an increasingly interesting associate 
in high grade gliomas (Cobbs et al. 2002; Mitchell et al. 2008; Dziurzynski et al.). Exosomes 
from CMV infected cells contain CMV antigens (eg, gB) that are capable of stimulating 
CD4+ memory T cells (Walker, Maier, and Pober 2009), and while CMV DNA was amplified 
from glioblastoma (GBM) patient peripheral blood in one study (Mitchell et al. 2008), no 
CMV DNA was detected in another similar (but smaller) study (Lehrer et al.). However, 
neither of these studies used patient serum exosomes as target materials. In a proteomic 
study of murine SMA-560 brain tumor cell-derived exosomes, we identified the gag 
polyprotein pr65 and its precursor (Graner et al. 2009); these proteins originate from an 
endogenous murine retrovirus implicated in the progression of murine melanoma by 
subversion of immune surveillance (Mangeney et al. 2005). Thus, there remain many 
implications of viruses, virons, or viral particles/pieces in circulating tumor exosomes either 
as immune targets (potential antigens) or as further purveyors of immune suppression. 
The roles of exosomes/microvesicles in bacterial diseases are less well studied, but there 
have been significant works in the mycobacter area. Exosomes from macrophage infected 
with Mycobacterium avium display antigens such as glycolipids from that pathogen. These 
exosomes provide pro-inflammatory signals to resting macrophage (Bhatnagar and Schorey 
2007), as is true of exosomes from a number of pathogenically infected macrophage both in 
vitro and in vivo (Bhatnagar et al. 2007). However, while exosomes from Mycobacterium 
tuberculosis-infected macrophage contain proteomically-identified TB proteins/antigens 
(Giri et al.), exosomes from MTB-infected macrophage can actually suppress activation of 
naïve macrophage (Singh et al.). While the similarities, particularly immune relationships, 
between cancer and MTB infection have not gone unnoticed (Broxmeyer 2004; Schorey and 
Bhatnagar 2008; Cocito and Maes 1998), the roles of exosomes and microvesicles in these 
diseases likely remains complex. 
Another intriguing (and perhaps frightening) role played by exosomes and microvesicles is 
in the neurodegenerative disease arena. Experimentally, prion diseases such as scrapie have 
been shown to be transmissible from infected cells (those with the prion protein, PrP, 
misfolded into the scrapie form, PrPsc) to uninfected cells by application of exosomes from 
the infected cells to the uninfected cells. PrPsc was found in the exosomes from the infected 
cells, and these cells initiated scrapie when injected into mice (Fevrier et al. 2004). PrP is a 
GPI-linked protein (Miesbauer et al.), and as mentioned above, membrane proteins with this 
lipid anchor are frequently sorted into lipid rafts that become part of the IVBs within MVBs, 
and eventually become exosomes. It is uncertain whether PrP converts to PrPsc in/on 
exosomes (Fevrier et al. 2005) but abnormal folding makes it a candidate for ubiquitination 
and thus sorting into MVBs/IVBs. Blood is considered the most common bodily fluid of 
transmission, but another study showed that at least the naturally occurring PrP protein is 
present in pseudo-afferent lymph fluid, and is preferentially enriched in CSF from sheep 
(Vella et al. 2008). Thus, there may be a neuronal reservoir for PrP (and PrPsc or other 
transmissible infectious prion forms) in exosomes found in CSF. For another 
neurodegenerative disease, Alzheimer’s disease (AD), the etiology is believed to be related 
to the cleavage of cell surface amyloid precursor protein APP by  and -secretases, 
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resulting in formation of a peptide called A. Rajendran et al (Rajendran et al. 2006) found 
that from cells transfected with expression vectors for APP, they could find A peptides in 
the extracellular medium in the context of exosomes. The cells processed APP to A 
endosomally, with A ending up in MVBs and extracellularly with exosomes.  In 
immunoelectron microscopy sections of brains from afflicted patients, AD plaques 
contained exosome-associated proteins (eg, ALIX), further suggesting the role of MVBs and 
the potential for exosome involvement in the disease. Exosomes from cells expressing APP 
were found to contain a number of the secretases necessary for processing of APP into its 
secreted form, as well as the different C-terminal forms of cleaved APP, as well as A itself 
(Sharples et al. 2008). -secretase inhibition resulted in less A accumulation in exosomes, 
suggesting a potential therapeutic approach, but also suggesting the biomarker potential of 
A in exosomes to diagnose AD. Thus, not only can pathogenic organisms utilize the 
exosome/microvesicle pathways for infectious transmission, disease “particles” may utilize 
them as well to passage from infected or diseased cells to unaffected cells, a novel form of 
transmission that does not require cell-to-cell contact. 
2.2.6 Drug Efflux: fat balls as HazMat crews 
In our proteomic analyses of medulloblastoma exosomes, transporter molecules constituted 
> 10% of the proteins identified (see Figure 3). Thus, it may not be surprising that 
exosomes/microvesicles may be exit vehicles for chemotherapeutic agents applied to cancer 
cells as a mechanism of resistance. A cisplatin-insensitive ovarian carcinoma cell subline was 
found to have greatly reduced lysosome size and activity compared to its cisplatin-sensitive 
original line, and that insensitive line produced more exosomes than the parent line (Safaei 
et al. 2005). Those exosomes contained a number of lysosomal markers as well as transport 
molecules. When the insensitive line was treated with cisplatin,  2.5 fold more drug was 
effluxed from the insensitive line than the sensitive one, and at least a portion of that was 
found in the insoluble exosome pellet from the spent culture medium. Chen et al (Chen, 
Posada et al. 2006) further implicated the endosomal/MVB pathway for egress of 
doxorubicin, demonstrating a role for VPS4a in MVB and exosome function and packaging 
of drug. There may also be a role for microvesicle-based drug efflux, since the plasma 
membrane plays a role in resistance to doxorubicin in the K562 leukemia cell line used in 
these studies (Chen et al. 2007). While exosomes and microvesicles may provide drug 
resistance mechanisms for tumor cells, one must also consider the possibility that in normal 
cells, exosomes/microvesicles may perform similar cellular detoxification roles to remove 
noxious small molecule compounds to protect normal cells, as well. 
2.3 Summary 
Exosomes and microvesicles are akin to miniature versions of the cell itself, possessing 
lipids, proteins, and even RNAs from the originating cell; some even refer to exosomes 
and microvesicles as “extracellular organelles”. These extracellular vesicles are intimately 
involved in the extracellular local and distal cross-talk between and amongst cell, tissues, 
and organs, and have a variety of functions associated with them. In particular, the 
relationships between cancer cells and associated “normal” cells, such as those of 
the endothelium, the microenvironment, and immune system, are all profoundly 
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3. Brain tumor exosomes and microvesicles: fat balls on the brain 
The primary literature on brain tumor extracellular vesicles is amazingly small (Graner, 
Cumming, and Bigner 2007; Al-Nedawi et al. 2008; Skog et al. 2008; Graner et al. 2009; 
Guescini, Genedani et al. ; Yang et al.), although one of the early microvesicle papers used C-6 
rat glioma cells and called their vesicular entities “exosomes”, but by current standards the 
vesicles would be called microvesicles or microparticles (Trams et al. 1981; Johnstone 2006). 
Our group was arguably the first to identify bona fide brain tumor exosomes, despite some 20 
years of previous study. Brain tumor exosomes and microvesicles appear structurally and 
proteomically like such vesicles from other cell/tumor types in culture, and from the sera of 
patients with diverse tumors (Graner, Cumming, and Bigner 2007; Graner et al. 2009; Al-
Nedawi et al. 2008; Skog et al. 2008). One difference has been that exosomes from both adult 
gliomas and pediatric medulloblastomas have proven extremely resilient to lysis and 
extraction (Graner et al. 2009) (M Graner, unpublished; Johan Skog, personal communication), 
making protein analysis in particular rather difficult. Another interesting feature is the 
putative presence of mitochondrial DNA contained within (and perhaps on the surface of) 
glioma cell line extracellular vesicles (Guescini, Genedani et al.), which has also been seen in 
murine myoblast vesicles as reported by the same group (Guescini, Guidolin et al.) ; this 
finding runs counter to other groups‘ findings (Valadi et al. 2007) and will likely be somewhat 
controversial. However, given the high glycolytic capacity of gliomas and the distressed and 
non-uniform appearance and activities of their mitochondria (Oudard et al. 1996; Oudard et al. 
1997; Ordys et al. ; Santandreu et al. 2008), relationships between exosomes and mitochondria 
in cancer cells could potentially be an area of fruitful and energetic study. In the next sections 
we will discuss the broad range signaling abilities, metabolic effects, and immunological 
properties of brain tumor exosomes/microvesicles, as well as the exosome-induced migratory 
and protective phenotypes cells experience upon exposure to exosomes. 
3.1 Brain tumor exosomes drive various activities in recipient cells: fat balls as game-
changers 
High grade gliomas such as glioblastomas (GBMs) are extremely heterogeneous with 
respect to cellular appearances and phenotypes, chromosomal abnormalities, gene and 
protein expression, etc, but almost universally share a lack of response to treatment 
(Mischel, Cloughesy, and Nelson 2004) whether the treatment is chemical, radiologic, or 
immunologic. Another commonality amongst GBMs is their extraordinary invasive 
potential that inevitably leads to tumor recurrence and patient demise (Hoelzinger, Demuth, 
and Berens 2007). Below we will describe mechanisms by which exosomes and 
microvesicles may contribute to these most nefarious features of high grade gliomas. 
3.1.1 Brain tumor exosomes and EGFR signaling: fat balls carry the mail 
The epidermal growth factor receptor (EGFR) has a long history as a major player and 
therapeutic target in brain tumors and many other tumors as well (Hatanpaa et al. ; Ye, Gao, 
and Cai ; Brandes et al. 2008; Vivanco and Mellinghoff ; Yarden 2001). Perhaps the most 
prominent mutation in EGFR in gliomas is the variant (either genomically mutated/encoded 
or resulting from a splice-site mutation and alternate usage) that eliminates exons 2-7 to yield 
“delta 2-7 EGFR” or “EGFR variant III” (EGFRvIII), reviewed in (Wikstrand et al. 1998; 
Pedersen et al. 2001; Sonabend, Dana, and Lesniak 2007).  This mutant EGFR does not 
necessarily need to dimerize to signal (Chu et al. 1997) , does not bind ligand but is nonetheless 
www.intechopen.com
 
Brain Tumor Exosomes and Microvesicles: Pleiotropic Effects from Tiny Cellular Surrogates 55 
constitutively active and is capable of inducing tumor growth in otherwise non-tumorigenic 
cells in animal models (Batra et al. 1995). EGFRvIII is expressed in 25%-67% of all GBMs 
(Pelloski et al. 2007; Heimberger et al. 2005) and is generally considered a marker of poorer 
prognosis. The receptor is heterogeneously expressed in human GBMs (generally pockets of 
expression) compared to the more uniform presence of the wild type EGFR (EGFRwt) 
(Nishikawa et al. 2004). Coupled with animal model studies, it is suspected that EGFRvIII 
results in both autocrine signaling loops that lead to enhance EGFRwt signaling (Ramnarain et 
al. 2006) and paracrine mechanisms driving increased proliferation of the bulk of the tumor 
mass (which expresses EGFRwt), thus maintaining tumor cell expression heterogeneity (Inda 
et al.). While one usually invokes soluble extracellularly-released signaling factors for these 
mechanisms, the work of Al-Nedawi (Al-Nedawi et al. 2008) indicates that tumor-derived 
microvesicles could carry and transfer EGFRvIII from cells that express the mutant receptor to 
cells that do not. This group transfected U373 cells to express the mutated EGFRvIII (these 
glioma cells normally express neither EGFR nor EGFRvIII) and collected microvesicles from 
the transfectants that displayed EGFRvIII. Recipient U373 [EGFRvII(-)] cells not only 
epigenetically “express” EGFRvIII following microvesicle receipt, but this also activates 
downstream signaling pathways associated with the presence of EGFRvIII including 
phosphorylation of ERK 1/2 and AKT, release of VEGF, increased Bcl-x expression with 
concurrent reduction in p27 expression, and enhanced soft agar colony formation. U373viii 
tumor-bearing mice also had EGFRvIII(+) microvesicles in their blood. We also found that 
murine glial tumor cells expressing EGFRvIII (SMA-560vIII) display the receptor on their 
exosome surfaces, and that patient serum exosomes/microvesicles (from 4 of 5 GBM patients) 
contained EGFRvIII, while all had EGFR in/on them (Graner et al. 2009). Skog et al (Skog et al. 
2008) also found EGFRvIII mRNA transcripts in microvesicles in sera from 7 of 25 patients 
with GBMs; 14 of 30 patients had transcript-positive tumor biopsies (and curiously, one 
patient had EGFRvIII(+) serum microvesicles but the biopsy was negative). They also found 
that GBM cell line microvesicles contained angiogenic factors and could stimulate brain 
endothelial cells to form tubules. These cumulative results beg the question as to whether the 
autocrine/paracrine signaling mechanisms and resultant enhanced tumor growth and features 
of aggressiveness may be in part due to the passage and reception of exosomes and 
microvesicles from EGFRvIII-expressing cells affecting ostensibly EGFRvIII(-) cells to enhance, 
maintain, or extend aggressive tumorigenic phenotypes. Aside from EGFR and the vIII 
mutant, exosomes and microvesicles are reservoirs of other factors potentially involved in cell-
cell signaling including L1-NCAM as we have shown. One of the highest scoring networks 
using Integrated Pathway Analysis from our proteomic efforts was “cell-to-cell signaling and 
interaction, cancer, hematologic system development and function” (Graner et al. 2009), 
implying that these vesicles have inherent signaling capacity or the ability to merge readily 
into signaling networks. Another important implication of the discovery of serum-borne 
tumor vesicles from patients with GBMs (and also, pediatric patients with medulloblastoma, 
data not shown) is that these vesicles escape the blood-brain barrier with potential for systemic 
effects, particularly involving immune function (Section 3.2). 
3.1.2 Brain tumor exosomes and metabolomics: fat balls grease the wheels of 
glycolysis 
Results from other brain tumor exosome/microvesicle experiments indicate that 
exogenously-added vesicles increase recipient tumor cell proliferation (Al-Nedawi et al. 
2008; Skog et al. 2008). We have seen similar dose-dependent results in modified 
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clonogenicity assays using U87MG cells while adding differential quantities of exosomes to 
those cells (Figure 4). 
 
 
Fig. 4. Exogenous tumor exosomes increase tumor cell proliferation in a dose-dependent 
manner. U87 glioma cells were grown under standard conditions for 48 hrs in the presence 
of 0, 25, or 100 g/ml exosomes and counted on a hemocytometer. Higher concentrations of 
exosomes significantly increased cell proliferation. 
Proliferation assays requiring redox readouts such as MTT/MTS assays in slower-growing 
cell lines pulsed with exosomes suggested that the proliferative effects may involve 
metabolic changes in the recipient cells, and our proteomics (Graner et al. 2009) (see also 
Figure 3) strongly suggested this also. We tested this by performing metabolomics 
experiments on U87MG cells grown in a stem cell-like medium with serum replacement; 
cells were treated (or not) with 25 g/ml exosomes for 44 hrs, and carbon flux was followed 
by incorporation of 13C-labeled glucose as a metabolic tracer for an additional 4 hrs. Media 
and cells were extracted and analyzed by nuclear magnetic resonance/magnetic resonance 
spectroscopy (NMR/MRS), notably revealing very large increases in energy transfer 
compounds and glycolytic activity (Figure 5)     
Decreased glutathione levels and increased lactate output are associated with 
transformation and metastasis in cell line models (Lu et al.); the lipid profile, with the 
exception of monounsaturated fatty acids (MUFA) and cholesterol, is remarkably stable. In a 
somewhat controversial finding in the literature, incubation of cells with oleic acid, a 
MUFA, promotes secretion of matrix metalloproteinase-9 (MMP9) and invasion of breast 
cancer cells (Soto-Guzman et al.). Whether there is an endogenous relationship between 
increased cellular MUFA production (as opposed to exogenous supplementation) and MMP 
activity/invasion remains to be seen, although it is possible that exosome lipid content may 
act in that supplementary fashion. Finally, the energy compounds and glycolysis profile, 
along with the soluble metabolite outputs, demonstrate that exosomes do indeed 
profoundly increase cellular metabolic activity in the form of glycolysis, in keeping with the 
Warburg effect (Ferreira). The mechanisms behind this need to be elucidated--is there 
increased enzymatic metabolic activity, or is there increased gene/protein expression of 
those enzymes, or are such enzymes actually delivered to the cells by exosomes (or any 
www.intechopen.com
 
Brain Tumor Exosomes and Microvesicles: Pleiotropic Effects from Tiny Cellular Surrogates 57 
combination of these scenarios)?  From our proteomic studies we have identified more than 
half of the enzymes in both the “preparatory” and “pay-off” phases of glycolysis (Graner et 
al. 2009) (and data not shown), along with a variety of other enzymes in other metabolic 
cycles. Thus, it is not inconceivable that exosomes themselves directly provide, or at least 
contribute to, some of the glycolytic enzyme repertoire that leads to enhanced glycolysis in 
tumor cells pulsed with exosomes. The general renewed interest in tumor metabolism 
(Cairns, Harris, and Mak) will hopefully prompt more research into the area of exosome 







Fig. 5. U87MG exosomes applied to U87 recipient cells results in increased glycolytic 
activity. U87 cells were incubated with 25 g/ml U87 exosomes for 44 hrs prior to changing 
the medium into medium containing 13C-labeled glucose for 4 hrs (blue bars). Control cells 
were grown without the addition of exosomes (red bars). Cells and media were harvested 
and extracted for soluble and lipid-based compounds, and analyzed by NMR/MRS for 
quantification and determination of carbon flux. A shows levels of soluble metabolites 
compared to control (untreated) U87MG cells; B shows lipid profile changes following 
exosome pulsing; C shows phosphate/energy compound changes during exosome 
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3.2 Brain tumor exosomes and immunology: fat balls vacillate between vaccines and 
vacuums 
As mentioned above (Section 2.2.1) tumor exosomes have gone from being seen as perfect 
vaccine material to their current status as infamous purveyors of immune suppression. Also 
as mentioned, most of those immune suppression studies have been performed in tissue 
culture settings that may not reflect the complexity of the mammalian immune system. 
Aside from our previous work demonstrating that murine brain tumor exosomes were 
potent prophylactic vaccines and drivers of antibody production (Graner et al. 2009), there 
has been only one other very recent study involving brain tumor exosomes and 
immunology (Bu et al.). That report determined that exosomes from culture supernatant of 
primary gliomas effectively provided antigens to autologous dendritic cells, which in turn 
could generate activated CD8+ T cells with potent cytotoxicity against autologous tumors 
cells in vitro. We pointed out in our publication (Graner et al. 2009) that there are a number 
of putative and known antigens in or on the glioma exosomes we utilized including the 
aforementioned EGFRvIII and glycoprotein nmb (GPNMB, also called osteoactivin, HGFIN, 
and DC-HIL). GPNMB is believed to be a bona fide antigen target in high grade gliomas 
(Kuan et al. 2006; Loging et al. 2000) and possibly in breast cancer (Rose et al.)  as well as in 
melanoma (Tse et al. 2006). The exosomes also had HSP70 on their vesicular surfaces along 
with HSPs 60, 90, calreticulin, and protein disulfide isomerase, all known immune 
stimulators or “danger signals”, and capable of providing antigens to DCs. However, those 
exosomes also had HSP25 (human HSP27) on their surfaces, which is associated with lower 
immunogenicity of exosomes (Alexzander Asea, personal communication) and more 
aggressive tumors when cell surface localized (Bausero et al. 2004). Also we found 
transforming growth factor beta (TGF-) with the exosomes, which is frequently associated 
with immune suppression (Flavell et al.); even the antigen GPNMB also has potential T cell 
inhibition activities (Tomihari et al.). Consequently, there seems to be a range of immune 
stimulatory and potentially immune suppressive moieties in/on the same population of 
exosomes. Also, quantity may be an issue. Our data suggest that tumor cell-derived 
exosomes at (relatively) low concentrations may inhibit interferon-gamma (IFN) release 
from mitogen-activated T cells, while at higher concentrations exosomes increase IFN 
release over control (mitogen-stimulated) T cells (Figure 6). Based on these data, context and 
quantity may be extremely relevant in the roles played by tumor exosomes in the double-
edged sword of immunity. One may imagine that if peripherally activated (eg, from a 
draining lymph node) circulating T cells encounter low concentrations of tumor exosomes 
also in the periphery, circulating in blood, those T cells may face the suppressive features of 
the exosomes. However, if the T cells are in the vicinity of high tumor exosome 
concentrations (tumor under stress, or in the context of a bolus of exosomes in the form of a 
vaccine following a priming protocol), this may switch the T cells to an even further 
activated phenotype. While that ostensibly should lead to better anti-tumor immunity, it 
may also lead to activation induced cell death (AICD) of the T cells.  
We found that tumor exosomes as antigen sources drive effective antibody production in 
short duration immunization protocols and with no adjuvant (Graner et al. 2009) (M Graner, 
unpublished) in mice. The significance of this in unclear; while antibody output is generally 
associated with Th2-type immune responses (ie, more regulatory than inflammatory), we 
nonetheless found IFN-producing T cells following tumor exosome vaccination concurrent 
with significant antibody titers against the exosomes (Graner et al. 2009). Similar enhanced 















Fig. 6. Medulloblastoma exosomes differentially and dose-dependently alter interferon-
gamma (IFN) release from mitogen activated human T cells. Peripheral blood mononuclear 
cells (PBMCs) were collected from a healthy donor and were stimulated with 
phytohemagglutinin (PHA) for 48 hrs (or not) in the presence of D283MED 
medulloblastoma exosomes harvested from tissue culture supernatants at the concentrations 
listed. After 48 hrs, media were harvested and IFN released from the cells was measured by 
specific ELISA. Statistical relationships (Student t tests) are shown. 
heat shock protein vaccines (Li et al. 2008; Manjili et al. 2003). The relevant question here is if 
the antibodies have any biologic, anti-tumor activity. In the situation of true human, pre-
established tumors, one may think of tumor-released exosomes acting as “auto-
immunizations” against tumor antigens. However, it may be that the tumor “sheds” 
antigens via exosomes/microvesicles, driving futile immune responses against “decoy” 
circulating antigens. This may have 2 benefits for the tumor—1) driving antibody responses 
may serve to maintain a Th2 cytokine environment, which is suboptimal for effective 
cellular anti-tumor immune responses; and 2) free-floating, released exosomes may titrate 
out potentially “dangerous” antibodies generated against tumor antigens, thus preventing 
those antibodies from ever reaching the solid tumor mass. Concepts similar to this are cited 
above (Battke et al.). As further evidence that tumors may “offer up” exosome-bound 
antigens we show here that antibodies in serum from a patient with GBM  show reactivity 
with the autologous tumor lysate on a Western blot but far more intense reactivity against 
the autologous serum exosomes (Figure 7) 
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Fig. 7. Patient serum antibodies react with autologous tumor lysate and serum 
exosomes/microvesicles. A patient with GBM had blood drawn at the time of tumor 
resection. Exosomes/microvesicles were harvested from the serum; the remainder of the 
serum was diluted 1:100 and used to probe reducing, denaturing gels/blots of tumor lysate 
and lysed serum exosomes (25 g loaded per lane). Secondary antibody was biotinylated 
anti-human IgA/G/M, and tertiary reagent was streptavidin HRP. ECL developing agent 
was used, and images captured on a FluroChem Imager. Molecular weight markers are 
shown to the left. 
We postulate that vaccination with exosomes, particularly in relatively naïve animals, may 
prompt effective antibody (and T cell) generation, but in situations where the tumor has had 
time to “self-vaccinate” by releasing tumor exosomes, the antibody repertoire may reflect 
immune editing and therefore actually benefit the tumor via “ironic immunity”. This 
concept bears further study, and such investigations are ongoing.  
Thus complex interplays between stimulation, suppression, and “decoy allocation” that tie 
the tumor to the host immune response are further complicated by the potential roles played 
by exosomes. With antigens and heat shock protein danger signals, exosomes may be good 
vaccines; however with TGF content and a host of other suppressive features, tumor-
released exosomes may ultimately skew the host immune response into a position that 
benefits the tumor by decoy antigen release and stealth regulatory cytokine environment. 
3.3 Brain tumor exosomes/microvesicles and tumor migration:  attractive fat balls 
blaze the trail 
Perhaps the most distressing activity performed by high grade gliomas is their ability to 
migrate and invade the parenchyma with devastating consequences of bilateral presentation 
if the tumor crosses the corpus callosum, with the possibility of disastrous leptomeningeal 
dissemination. The modulation of the extracellular environment, and the ability to 
proximally and distally signal extracellularly are critical factors in this manifestation of the 
glioma phenotype (Nakada et al. 2007; Berens and Giese 1999).  The cells may migrate out of 
the range of focused external beam radiation therapy, thus limiting its usefulness, and this 
migration is a clear danger in the multifocal recurrences more and more frequently seen 
following treatment with bevacizumab (Rahman et al. ; Iwamoto et al. 2009; de Groot et al. ; 
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Verhoeff et al. 2009). Obviously, glioma invasion makes truly complete surgical resections 
impossible. Exosomes and microvesicles, as nanovesicles released into the extracellular 
environment, seem like perfect vehicles for extracellular remodeling, possessing proteases 
such as insulin degrading enzyme (IDE) (Tamboli et al.), MMPs 1 and 14 (Medina and 
Ghahary ; Hakulinen et al. 2008)  and ADAMs 10 and 17  (Mathews et al. ; Stoeck et al. 2006). 
Exosomal Rabs (Hendrix et al.), HSP90 and plasminogen (McCready et al.),  and 
tetraspanins (Rana et al.) have been implicated in tumor cell migration/invasion as well. 
Recently it was shown that L1-NCAM (CD171) and its migration-inducing cleavage product 
were found in exosomes of brain tumor cell lines (Yang et al.), and exosomes were partially 
involved in an animal model of tumor metastasis by preparation of the pre-metastatic niche  
(Jung et al. 2009). Amidst this background we have determined that glioma exosomes (from 
U87MG cells, as well as D283MED cells—not shown) can promote tumor cell migration 
across a plastic membrane at higher levels than that promoted by FBS (Figure 8) 
 
 
       
Fig. 8. Glioma exosomes promote tumor cell migration in Boyden chamber assays and 
possess intrinsic matrix metalloproteinase activities. Left  U87MG cells were placed on the 
top chamber of an 8 m pore-size plastic insert in wells; the lower chambers contained 
serum-free media, fetal bovine serum (FBS, positive control) or increasing quantities of U87 
exosomes. Cells  migrated for 24 hrs; the inserts were removed, the tops washed, and the 
bottoms were stained with crystal violet, and 5 random fields of duplicate wells were 
counted (avg, SD, and t test results shown). Right U87 exosomes were separated in a 
zymogram (gelatin) gel; MMP activation was induced, and cleared areas in the gel 
correspond to gelatinase activities  of appropriate molecular weights for MMPs 2, 9, and 14 
(confirmed by Western blotting, data not shown). 
The Boyden chamber/migration assay is largely an attraction assay; the complexity of 
exosomes/microvesicles will make it interesting to determine what factors in or on these 
vesicles promote this migration and potentially could serve as attractants over a larger 
distance, akin to leaving “bread crumbs” of exosomes for cells to track and follow while 
migrating or metastasizing. The MMP activities suggest that exosomes will be able to also 
carve paths and remodel the extracellular matrix to allow for cells to migrate (either tumor 
cells out of the main mass, or even endothelial cells in for angiogenic events). These 
preliminary data indicate that brain tumor exosomes can both blaze paths and provide 
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attraction for glioma migration. As this is an important area of therapeutic attention, 
exosome biology may play a critical role in our attempts to regain local control of high grade 
gliomas following surgery, thus improving recurrent-free survival. 
3.4 Brain tumor exosomes/microvesicles and chemoresistance: fat balls provide 
protection 
High grade gliomas are extremely chemoresistant (Lu and Shervington 2008; Sarkaria et al. 
2008). As mentioned above (Section 2.2.6), exosomes have transporter molecules among 
their proteomic content, and we have also shown that MRP3 is in glioma exosomes (Graner 
et al. 2009). These may provide mechanisms for drug export, literally packaging the 
chemotherapeutic agent in exosomes/microvesicles. As shown above (Section 3.1.2), 
exosomes may also accelerate metabolic activity which could lead to increased breakdown 
or chemical modification of the drug compound. While these mechanisms are undoubtedly 
important in glioma chemoresistance (along with the natural protection of the blood-brain 
barrier), no one has ever demonstrated an impact of exosomes on cellular resistance to drugs 
in neuro-oncology. Since all of this discussion is currently theoretical, we have first tested 
this putative protective property of exogenously-added exosomes and have discovered that 
glioma exosomes can indeed provide protection or enhance resistance to temozolomide 
(Figure 9). In fact, even low concentrations of tumor exosomes fully complemented cell 
growth back to normal despite the presence of the drug (which is the chemotherapy of 
choice for high grade gliomas and is a component of the current standard of care for these 
tumors) (Stupp et al. 2005). 
 
 
Fig. 9. Exogenously added tumor exosomes protect glioma cells from cytotoxic 
chemotherapy. U87MG cells were either left untreated (“Cells only”) or were subjected to 
treatment with temozolomide/Temodar® (“TMZ”) at 200 nM concentrations for 48 hrs. 
Exosomes at the concentrations listed were also added (or not), and cell growth was 
quantified in a modified clonogenicity assay as describe for Figure 4. Exosomes provide 
significant protection against the chemotherapy agent, and return cell growth to normal (+ 
exosomes, not significant compared to cells only). 
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Exosomes, by currently unknown mechanisms, provide some means of chemoresistance to 
the therapeutic drug of choice as the standard of care for high grade gliomas. However, this 
does strongly suggest that discovering this underlying mechanism may be a critical point 
for improving therapeutic efficacy of our drug treatments. This may go back to the cellular 
mechanisms for generating exosomes; however, as this is a process common apparently 
almost all cells, it is unclear if there are particular aspects that are tumor-specific. Iero et al 
(Iero et al. 2008) have suggested that a number of pharmacologic agents may be able to 
interfere with exosome release, but so far this does not appear to have made an impact in 
most of our current chemotherapy regimens. 
3.5 Summary 
Exosomes and microvesicles from brain tumor cells affect signaling capacities, alter 
metabolism, impinge on immunity, and may promote two of the most nefarious 
characteristics of high grade gliomas (and medulloblastomas)—their abilities to migrate and 
invade normal tissue, and their inherent resistance to treatment. Obviously, there is a 
tremendous space for research in this area as well as a great need to understand these 
complex vesicles and their interactions with the tumor, the tumor microenvironment, the 
normal tissues, and the potential systemic effects as the tumor attempts to control its 
surroundings locally and distally. 
4. Conclusions 
Exosomes and microvesicles serve as unique and profoundly important extracellular 
signaling vehicles both locally in the area of release, as well as at potentially great distances 
via the circulatory system. Despite some 20 years of research efforts devoted to these “fat 
balls”, we are finding more and more fascinating features about them almost constantly. 
With intense study of the biochemical compositions of the vesicles (proteomics, ribonomics, 
lipidomics) we are learning more about the similarities, as well as the curious differences, 
between exosomes from different cellular sources. We are also developing much better 
understandings of the biology of vesicular formation and release—something that many 
viruses and pathogens have long exploited. All of this knowledge complements the ongoing 
work to understand our ever-increasing—and increasingly fascinating--knowledge of the 
biologic impacts that exosomes and microvesicles have on recipient cells, and on micro- and 
macroenvironments. From the perspective of neuro-oncology, there is a wealth of 
information waiting to be mined, particularly in the areas of immunology, proximal and 
distal cell signaling, microenvironment alteration for migration or protection, and how 
tumor cells may use the physiology of exosomes as a means of therapeutic resistance. The 
almost viral quality of exosomes and microvesicles as carriers of messenger and microRNAs 
is one example of a vastly open region ripe for progress, and it almost certainly intersects 
with many other areas of research. As studies of exosomes and microvesicles become 
accepted as legitimate science and gain mainstream appreciation, we should see further 
advances in the research that leads to translational applications of this knowledge. 
Interdisciplinary approaches will be required as expertise in genetics, proteomics,  
metabolomics, lipid biochemistry, and microparticle/nanovesicle technologies all have a 
place in these endeavors. For patients facing the dismal prognoses of brain tumors, new 
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